# IAPO4Rec'd BGT620 AUG 2008 652

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 12, 2008

NUS 2 0 2008

By: Mari Kleineidam

Mari Kleineidam

PATENT Attorney Docket No. GC819-2-US/B

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ) Group Art Unit: 1632 )

Jones, Brian E. et al. ) Examiner: Not yet assigned )

Serial No.: 10/576,331 ) Confirmation No.: 7214 )

Filed: July 18, 2007 )

For: SERINE PROTEASES, NUCLEIC ACIDS ENCODING SERINE ENZYMES AND VECTORS AND HOST CELLS INCORPORATING SAME

### TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

Enclosed are the following documents:

Information Disclosure Statement (3 page(s), in duplicate);
 Form PTO 1449 (7 page(s)); and

Not Provided

 Copies of lot references. and International Search Report in corresponding PCT Application No. PCT/US2004/039066.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required, or credit any overpayment to Deposit Account No. 07-1048, referencing Attorney Docket No. GC819-2-US/B. A duplicate of this paper is enclosed.

Respectfully submitted,

Dated: 12 August 2008

Kamrin T. MacKnight
Reg. No. 38.230

Danisco US Inc., Genencor Division 925 Page Mill Road Palo Alto, CA 94304-1013 Tel.: (650) 846-5838

Fax: (650) 845-6504 /Sheridan Swope/

07/18/2011

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mall in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 12, 2008 By: Mr. L. Life included

Mari Kleineidam

NUE 2 0 2008 IN

# PATENT Attorney Docket No. GC819-2-US/B

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ) Group Art Unit: 1632 )
Jones, Brian E. et al. ) Examiner: Not yet assigned Serial No.: 10/576,331 ) Confirmation No.: 7214 )
Filed: July 18, 2007 )
For: SERINE PROTEASES, NUCLEIC ACIDS ENCODING SERINE ENZYMES AND VECTORS AND HOST CELLS INCORPORATING SAME

#### TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

Enclosed are the following documents:

1. Information Disclosure Statement (3 page(s), in duplicate);

Not provided

 Form PTO-1443 (7 page(s)), and
 Copies of loi references, and International Search Report in corresponding PCT Application No. PCT/US2004/039066.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required, or credit any overpayment to Deposit Account No. 07-1048, referencing Attorney Docket No. GC819-2-US/B. A duplicate of this paper is enclosed.

Respectfully submitted.

Dated: 12 August 2008

Kamrin T. MacKnight
Reg. No. 38,230

Danisco US Inc., Genencor Division 925 Page Mill Road Palo Alto, CA 94304-1013 Tel.: (650) 846-5838

07/18/2011

Fax: (650) 845-6504 /Sheridan Swope/

GC819-2-US/B T-IDS

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexangria, VA 22313-1450 on the date indicated below.

Date: August 2008 By: Man Gleiger dam



PATENT Attorney Docket No. GC819-2-US/B

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of		) Confirmatio	Confirmation No.: 7214 Group Art Unit: 1632 Examiner: Not yet assigned
Jones, Brian E. et al. Serial No.: 10/576,331		) ) Group Art U	
Filed: July 18, 2007		) Examiner: I	
For:	SERINE PROTEASES, NUCLEIC ACIDS ENCODING SERINE ENZYMES AND VECTORS AND HOST CELLS INCORPORATING SAME	; ) )	

# INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a)	accompanies the new patent application submitted herewith.	37
CFR §	1.97(a).	

- (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c)  $\boxtimes$  as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

	applica known notice (\$180. §1.97( 1048 ii	is filed after the first Office Action and more than three months after the ation filing date or PCT national stage date of entry filing but, as far as is to the undersigned, prior to the mailing date of either a final rejection or a of allowance, whichever occurs first, and is accompanied by either the fee 00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR e), as checked below. Authorization to charge Deposit Account No. 07-1 the amount of \$180.00 to cover the cost of this Information Disclosure tent is provided in the Transmittal Letter submitted herewith in duplicate.			
	allowa theTra No. 07 as spe consid	is filed after the mailing date of either a final rejection or a notice of noce, whichever occurred first, and is accompanied by authorization (in nsmittal Letter submitted herewith in duplicate) to charge Deposit Account -1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification cified in 37 CFR §1.97(e), as checked below. This document is to be dered as a petition requesting consideration of the Supplemental nation Disclosure Statement.			
[If either of boxes (d) or (e) is checked above, the following "certification" under					
37 CFR §1.9	37 CFR §1.97(e) must be completed.] The undersigned certifies that:				
	office	Each item of information contained in the Information Disclosure ment was cited in a communication mailed from a foreign patent in a counterpart foreign application not more than three months prior filing of this Information Disclosure Statement.			
	office under design	No item of information contained in this Information Disclosure ment was cited in a communication mailed from a foreign patent in a counterpart foreign application and to the knowledge of the signed after making reasonable inquiry, was known to any individual nated in 37 CFR §1.56(c) more than three months prior to the filing Information Disclosure Statement.			
A copy of the	items	on Form PTO-1449 is supplied: PCT International Search Report			
for PCT/US2	004/03	9066, mailed September 5, 2005 with attached patents and			
publications.					
□ each  none  only those listed below:					
A concise explanation of relevance of the items listed on PTO-1449 is:					
	$\boxtimes$	not given			
		given for each listed item			
		given for only non-English language listed item(s)			
		in the form of an English language copy of a Search Report from a foreign office, issued in a counterpart application, which refers to the relevant as of the references.			

USSN: 10/576,331 Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Kamrin T. MacKnight Reg. No. 38.230

Dated: 12 August 2008

Danisco US, Inc., Genencor Division 925 Page Mill Road Palo Alto, CA 94304-1013 Phone: (650) 846-5838

Fax: (650) 845-6504

I hereby certify that this correspondence is being deposited with the US Postal S	ervice with sufficient
postage as First Class Mail in an envelope addressed to Mail Stop Amendment,	
P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.	

Date: August 12, 2008 By: Mai Klainakian



PATENT Attorney Docket No. GC819-2-US/B

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of		)	0 5 5 11 7044
Jones, Brian E. et al.		)	Confirmation No.: 7214
Serial No.: 10/576,331		)	Group Art Unit: 1632
Filed: July 18, 2007		)	Examiner: Not yet assigne
For:	SERINE PROTEASES, NUCLEIC ACIDS ENCODING SERINE	)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SAME

ENZYMES AND VECTORS AND HOST CELLS INCORPORATING

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a)	accompanies the	new patent	application	submitted herewith.	. 37
CFR §	1.97(a).				

(b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.

(c)  $\boxtimes$  as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

GC819-2-US/B IDS

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

•	
6 	d) is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee \$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.
,	(e) is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.
[If either of b	oxes (d) or (e) is checked above, the following "certification" under
37 CFR §1.97	7(e) must be completed.] The undersigned certifies that:
	Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
A copy of the	items on Form PTO-1449 is supplied: PCT International Search Report
for PCT/US2	004/039066, mailed September 5, 2005 with attached patents and
publications.	
🛚 ea	ch ☐ none ☐ only those listed below:
A concise exp	lanation of relevance of the items listed on PTO-1449 is:
	given for each listed item
	given for only non-English language listed item(s)
	in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

USSN: 10/576,331 Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Dated: 12 August 2008

Danisco US, Inc., Genencor Division 925 Page Mill Road Palo Alto, CA 94304-1013 Phone: (650) 846-5838 Fax: (650) 845-6504 Kamrin T. MacKnight Reg. No. 38,230

/Sheridan Swope/

07/18/2011